Roundtable Discussion: Where Should the Field Place Its Next Bet? Prioritising the Next Generation of Radiopharmaceutical Targets

Key Questions to Be Addressed:

• Should the field continue investing in established targets, or is it time to prioritise first-in-class biology despite the increased risk?
• What level of biological, translational and preclinical evidence is needed before advancing a novel radiopharmaceutical target into IND-enabling studies?
• What lessons can be learned from targets that failed to translate clinically, and how should these shape future target selection and portfolio strategies?